Decitabine/Cedazuridine

地西他滨/西达尿苷

Report date: 2026/05/14 20:00:28

Base Information

Drug NameDecitabine/Cedazuridine
Drug Alias NameCedazuridine/地西他滨Cedazuridine and DecitabineDecitabine/CedazuridineDecitabine and CedazuridineCedazuridine/Decitabine +[14] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA (cytosine-5)-methyltransferase 1 inhibitorsCytidine deaminase inhibitors
TargetsDNA (cytosine-5)-methyltransferase 1Cytidine deaminase
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCytopenia +[13] 
Global Approved IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/07/07
Country/TerritoryCzechiaArmeniaBulgaria +[19] 
CombinationsYes DecitabineCedazuridine
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstex Pharmaceuticals IncNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteAstex Pharmaceuticals IncOtsuka Pharmaceutical Co Ltd +[6] 
Inactive CompaniesWashington University School Of Medicine
Active IndicationsMetastatic breast cancerSolid tumoursCytopenia +[11] 
Inactive IndicationsMesotheliomaNeoplasms

Other Information

ATC CodeL01XY
Related LinksWikipediaKEGG